Search clinical trials for: AZD0837

Total 83 results

National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx and other conditions

United States
National Cancer Institute (NCI)

Completed

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

Canada
Tony Eissa
University of Texas; University of Cincinnati

Completed

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Pulmonary Lymphangioleiomyomatosis

United States
Amsterdam UMC, location VUmc
AstraZeneca; Brigham and Women's Hospital; University of Oxford; Klinikum Garmisch-Patenkirchen and other collaborators

Recruiting

Saracatinib Trial TO Prevent FOP (STOPFOP)

Fibrodysplasia Ossificans Progressiva

Germany, Netherlands, United Kingdom
AstraZeneca

Completed

Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers

Healthy

United Kingdom
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers

Alcohol Drinking

United States
National Cancer Institute (NCI)

Terminated

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
National Cancer Institute (NCI)

Completed

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer

United States
NCIC Clinical Trials Group
AstraZeneca

Completed

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Pancreatic Cancer

Canada
AstraZeneca

Completed

Effect of Ketoconazole on Biliary Excretion of AZD0837

Healthy

Sweden
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Saracatinib and Alcohol Drinking

Alcohol Drinking

United States
National Cancer Institute (NCI)

Terminated

Saracatinib in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2)

Advanced ER-Positive HER2-Negative Breast Cancer

United States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
AstraZeneca

Completed

Phase I Study in Patients With Solid Tumours

Neoplasms

France, United Kingdom, Netherlands, Norway
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
AstraZeneca

Completed

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Neoplasms

Germany
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
AstraZeneca

Completed

AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer (OVERT-1)

Ovarian Neoplasms | Ovarian Cancer

Bulgaria, Peru, Russian Federation, Romania, Norway, Canada, Denmark, Netherlands, Portugal, United Kingdom, France, Spain
AstraZeneca

Completed

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

Breast Cancer | Bone Neoplasms | Prostate Cancer

United States, United Kingdom, Sweden, Norway, Canada, Portugal, Denmark, Spain
AstraZeneca

Completed

Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)

Persistent or Permanent Non-valvular Atrial Fibrillation

Sweden, Poland, Russian Federation, United Kingdom, Norway, Denmark
AstraZeneca

Withdrawn

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

Cancer | Non Small Cell Lung Cancer | Epithelial Ovarian Cancer

Japan
AstraZeneca

Completed

Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam

Healthy Volunteers

United Kingdom
Joyce Marie Slingerland
Stanford University

Completed

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Breast Cancer

United States
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

Healthy Subjects

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole

Healthy Volunteers

United Kingdom
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Belgium, Canada, Korea, Republic of, Portugal, France, United Kingdom, China, Germany, Japan, Mexico, Thailand, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Poland, Romania, Chile, Sw... and more
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States, Singapore, Australia
National Institute of Allergy and Infectious Diseases...

Completed

Phase 2a EBA Trial of AZD5847

Tuberculosis

South Africa
AstraZeneca

Completed

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Healthy Volunteers

United States
Duke University
National Institutes of Health (NIH)

Completed

Treatment of Mood and Marriage Study (TOMMS)

Major Depressive Disorder | Partner Relational Disorder (V61.10)

United States

Search clinical trials for: AZD0837

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations